Kinoxis Therapeutics Pty Ltd.

Ginkgo Bioworks is the second computational-focused target discovery company to link up with Boehringer Ingelheim in the last month. Ginkgo Bioworks and Boehringer Ingelheim are linking arms as they venture into the forest of undruggable targets, with the larger pharma offering up to $406 million for Ginkgo’s molecules.  Ginkgo will also receive an undisclosed upfront fee for its R&D efforts, according to an announcement Monday. The two companies did not elaborate on how many targets Ginkgo was obligated to identify but said the $406 million is the aggregate amount of biobucks the biotech stands to gain.  The deal allows Boehringer to take a pickax to Ginkgo’s Codebase, a library of more than three terabases of sequencing data, in order to identify potential therapies. One terabase is equal to the genetic sequencing data of 1 trillion base pairs.  The collaboration is the latest in an expansive business development effort from Ginkgo, with a recent focus on gene therapy. A month ago, the company bought AAV capsid maker StrideBio for its intellectual property. The hope is that Stride’s platform could be used for future partnerships to help other companies find new therapies. Ginkgo explicitly said it wasn’t interested in Stride’s preclinical asset and plans to out-license or sell it.  “We're not moving into clinical development,” Anna Marie Wagner, Ginkgo’s head of corporate development, said at the time.  Boehringer has been equally aggressive on the partnership front as of late, most recently collaborating with Melbourne-based biotech Kinoxis Therapeutics to develop new neuropsychiatry treatments. Boehringer offered up to $181 million in milestone payments for that deal. The German pharma has also used licensing deals to try to bolster its oncology franchise, partnering with Covant Therapeutics in late March to work on an ADAR1 inhibitor in exchange for up to $481 million.  Ginkgo is the second computational-focused target discovery company to link up with Boehringer in the last month, after NaturalAntibody announced an antibody-focused discovery pact in early April. Financial terms of the deal were not included when it was announced. 

DUBLIN--( BUSINESS WIRE )--The "Opium (Opioid) Addiction Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update" report has been added to ResearchAndMarkets.com's offering. This report provides top line data relating to the clinical trials on Opium (Opioid) Addiction. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The publisher's Clinical Trial Reports are generated using the publisher's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Scope The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months Reasons to Buy Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level Key Topics Covered: Report Guidance Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials and Average Enrollment by Country Clinical Trials by G7 Countries: Proportion of Opium (Opioid) Addiction to Central Nervous System Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Opium (Opioid) Addiction to Central Nervous System Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Opium (Opioid) Addiction Therapeutics Clinical Trials Prominent Drugs Clinical Trial Profile Snapshots Appendix Companies Mentioned Indivior Plc Alkermes Plc Novo Holdings AS Orexo AB Titan Pharmaceuticals Inc Mundipharma International Ltd Collegium Pharmaceutical Inc Novartis AG Pfizer Inc Emmes Co LLC For more information about this report visit https://www.researchandmarkets.com/r/drs8lb Source: GlobalData About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.